# Daratumumab in STK11 Mutated NSCLC

> **NCT05807048** · PHASE2 · COMPLETED · sponsor: **NYU Langone Health** · enrollment: 8 (actual)

## Conditions studied

- Non-small Cell Lung Cancer With STK11/LKB1 Mutation

## Interventions

- **DRUG:** Daratumumab and Hyaluronidase-fihj
- **DRUG:** Pre-Intervention Medication
- **DRUG:** Post-Intervention Medication

## Key facts

- **NCT ID:** NCT05807048
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-01
- **Primary completion:** 2025-11-11
- **Final completion:** 2025-11-11
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05807048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05807048, "Daratumumab in STK11 Mutated NSCLC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05807048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*